연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
991. Concurrent p16 methylation pattern as an adverse prognostic factor in multiple myeloma: a methylation-specific polymerase chain reaction study using two different primer sets.
Park G, Kang SH, Lee JH, Suh C, Kim M, Park SM, Kim TY, Oh B, Min HJ, Yoon SS, Yang IC, Cho HI, Lee DS; Korean Multiple Myeloma Working Party (KMMWP).
Ann Hematol. 2011 Jan;90(1):73-9.
Link
990. Validation of limited lymphadenectomy for lower-third gastric cancer based on depth of tumour invasion.
Kong SH, Yoo MW, Kim JW, Lee HJ, Kim WH, Lee KU, Yang HK.
Br J Surg. 2011 Jan;98(1):65-72.
Link
989. The role of indoleamine 2,3-dioxygenase in retinal pigment epithelial cell-mediated immune modulation.
Park CY, Yang SH, Chuck RS, Gehlbach PL, Park CG.
Ocul Immunol Inflamm. 2010 Jan;18(1):24-31.
Link
988. High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.
Rhee J, Han SW, Cha Y, Ham HS, Kim HP, Oh DY, Im SA, Park JW, Ro J, Lee KS, Park IH, Im YH, Bang YJ, Kim TY.
Breast Cancer Res Treat. 2011 Jan;125(1):107-14.
Link
987. Human sodium/iodide symporter-mediated radioiodine gene therapy enhances the killing activities of CTLs in a mouse tumor model.
Jeon YH, Choi Y, Kim CW, Kim YH, Youn H, Lee J, Chung JK.
Mol Cancer Ther. 2010 Jan;9(1):126-33.
Link
986. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras.
Oh JS, Kim JJ, Byun JY, Kim IA.
Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):5-8.
Link
985. Naturally occurring hepatitis B virus X deletions and insertions among Korean chronic patients.
Lee SA, Mun HS, Kim H, Lee HK, Kim BJ, Hwang ES, Kook YH, Kim BJ.
J Med Virol. 2011 Jan;83(1):65-70.
Link
984. Novel F141L pre-S2 mutation in hepatitis B virus increases the risk of hepatocellular carcinoma in patients with chronic genotype C infections.
Mun HS, Lee SA, Kim H, Hwang ES, Kook YH, Kim BJ.
J Virol. 2011 Jan;85(1):123-32.
Link
983. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
Kim DW, Lee SH, Lee JS, Lee MA, Kang JH, Kim SY, Shin SW, Kim HK, Heo DS.
Lung Cancer. 2011 Jan;71(1):65-9.
Link
982. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.
Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY.
Br J Cancer. 2009 Jan 27;100(2):298-304. Epub 2009 Jan 6.
Link